We investigated the use of the endocannabinoid anandamide as a means of cardioprotection against doxorubicin-induced cardiac dysfunction. Male rats received doxorubicin with or without anandamide pretreatment. Cardiac function was assessed in vivo using transthoracic echocardiography and ex vivo using the isolated working heart 5 days posttreatment. Doxorubicin administration without anandamide pretreatment resulted in a decline in fractional shortening (P < .05) and left ventricular wall thickness when compared to controls (P < .05). Ex vivo cardiac function analysis revealed a reduction in left ventricular developed pressure in hearts from animals receiving doxorubicin without anandamide pretreatment when compared to controls (P < .05). Left ventricles from animals receiving anandamide pretreatment before doxorubicin administration did not exhibit depressed fractional shortening, ventricular wall thickness, or developed pressure when compared to controls (P > .05). These results suggest that a potential therapy for doxorubicin-induced cardiotoxicity involves targeting the endogenous cannabinoid system.
Iarussi D., Indolfi P., Casale F., Martino V., Di Tullio MT, Calabro R.Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs. 2005;7:67-76.
2.
Lipshultz SE , Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia . J Clin Oncol. 2005;23:2629-2636.
3.
Monti E., Prosperi E., Supino R., Bottiroli G.Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res. 1995;15:193-197.
4.
Nousiainen T. , Jantunen E., Vanninen E., Hartikainen J.Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697-1700.
5.
Cole MP, Chaiswing L., Oberley TD, et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006; 69:186-197.
6.
Spallarossa P., Garibaldi S., Altieri P., et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37:837-846.
7.
DeAtley SM, Aksenov MY, Aksenova MV, et al. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett. 1999;136:41-46.
8.
Yen HC, Oberley TD, Vichitbandha S., Ho YS, St Clair DKThe protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 1996;98:1253-1260.
9.
Muraoka S., Miura T.Thiol oxidation induced by oxidative action of adriamycin. Free Radic Res. 2004;38: 963-968.
10.
Zucchi R., Danesi R.Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents. 2003;3:151-171.
11.
Andreadou I. , Sigala F., Iliodromitis EK, et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol. 2007;42:549-558.
12.
Tesoriere L. , Ciaccio M., Valenza M., et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther. 1994;269:430-436.
13.
Hayward R., Hydock DSDoxorubicin cardiotoxicity in the rat: an in vivo characterization . J Am Assoc Lab Anim Sci. 2007;46:20-32.
14.
Neilan TG, Doherty GA, Chen G., et al. Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. Am J Physiol Heart Circ Physiol . 2006;291:H532-H536.
15.
Chicco AJ, Hydock DS, Schneider CM, Hayward R.Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2006 ;100:519-527.
16.
Chicco AJ, Schneider CM, Hayward R.Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol. 2005;289:R424-R431.
17.
Chicco AJ, Schneider CM, Hayward R.Exercise training attenuates acute doxorubicin-induced cardiac dysfunction . J Cardiovasc Pharmacol. 2006;47:182-189.
18.
Ascensao A. , Ferreira R., Oliveira PJ, Magalhaes J.Effects of endurance training and acute Doxorubicin treatment on rat heart mitochondrial alterations induced by in vitro anoxia-reoxygenation . Cardiovasc Toxicol. 2006;6:159-172.
19.
Hasinoff BBDexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncol. 2006; 2:15-20.
20.
Cusack BJ, Gambliel H., Musser B., et al. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother Pharmacol. 2006;58:517-526.
21.
Agapito MT, Antolin Y., del Brio MT, Lopez-Burillo S., Pablos MI, Recio JMProtective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res. 2001;31:23-30.
Breed JG, Zimmerman AN, Dormans JA, Pinedo HMFailure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res. 1980;40:2033-2038.
24.
Wagner JA, Abesser M., Harvey-White J., Ertl G.2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol. 2006;47:650-655.
25.
Underdown NJ , Hiley CR, Ford WRAnandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism . Br J Pharmacol. 2005 ;146:809-816.
26.
Wagner JA, Hu K., Karcher J., et al. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol. 2003;138:1251-1258.
27.
Bisogno T., Melck D., Bobrov M., et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000; 351:817-824.
28.
Bouchard JF, Lepicier P., Lamontagne D.Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci . 2003;72:1859-1870.
29.
Sterin-Borda L., Del Zar CF, Borda E.Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol. 2005;69:1705-1713.
30.
Di Filippo C., Rossi F., Rossi S., D'Amico M.Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol. 2004; 75:453-459.
31.
Lepicier P. , Bouchard JF, Lagneux C., Lamontagne D.Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol . 2003 ;139:805-815.
32.
Iliodromitis EK, Aggeli IK, Gaitanaki C., et al. p38-MAPK is involved in restoration of the lost protection of preconditioning by nicorandil in vivo. Eur J Pharmacol. 2008; 579:289-297.
33.
Ping P., Zhang J., Huang S., et al. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits. Am J Physiol. 1999;277: H1771-H1785.
34.
House SL, Melhorn SJ, Newman G., Doetschman T., Schultz Jel J.The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol. 2007;293:H354-H365.
35.
Arola OJ, Saraste A., Pulkki K., Kallajoki M., Parvinen M., Voipio-Pulkki LMAcute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis . Cancer Res. 2000; 60:1789-1792.
36.
Jones SM, Kirby MS, Harding SE, et al. Adriamycin cardiomyopathy in the rabbit: alterations in contractile proteins and myocyte function. Cardiovasc Res. 1990; 24:834-842.
37.
Batkai S., Mukhopadhyay P., Harvey-White J., Kechrid R., Pacher P., Kunos G.Endocannabinoids acting at cb1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol . 2007;293:H1689-H1695.
38.
Mukhopadhyay P., Batkai S., Rajesh M., et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007;50:528-536.
39.
Batkai S., Osei-Hyiaman D., Pan H., et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/ reperfusion injury. FASEB J. 2007;21:1788-1800.
40.
Belham M., Kruger A., Mepham S., Faganello G., Pritchard C.Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail. 2007;9:409-414.
41.
Takemura G. , Fujiwara H.Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis . 2007;49:330-352.
42.
Outomuro D. , Grana DR, Azzato F., Milei J.Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol. 2007;117:6-15.
43.
Kaiserova H. , Simunek T., Sterba M., et al. New iron chelators in anthracycline-induced cardiotoxicity. Cardiovasc Toxicol . 2007;7:145-150.
44.
Bjelogrlic SK, Radic J., Jovic V., Radulovic S.Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice. Basic Clin Pharmacol Toxicol. 2005 ; 97:311-319.
45.
Lebrecht D. , Geist A., Ketelsen UP, Haberstroh J., Setzer B., Walker UADexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol . 2007;151:771-778.
46.
Conklin KACoenzyme q10 for prevention of anthracycline-induced cardiotoxicity . Integr Cancer Ther. 2005;4:110-130.
47.
Rivera E.Liposomal anthracyclines in metastatic breast cancer: clinical update . Oncologist. 2003;8(suppl 2):3-9.
48.
Lorusso V., Manzione L., Silvestris N.Role of liposomal anthracyclines in breast cancer. Ann Oncol.2007; 18(suppl 6):vi70-vi73.
49.
Hydock DS, Lien C.-Y, Schneider CM, Hayward R.Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction . Med Sci Sports Exer. 2008; 40:808-817.
